欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2021, Vol. 26 ›› Issue (7): 802-807.doi: 10.12092/j.issn.1009-2501.2021.07.012

• 综述与讲座 • 上一篇    下一篇

早期临床试验的伦理问题及对策探讨

欧阳晨溪1,黄洁2,3,项玉霞2,3,王晓敏2,3,4   

  1. 1湖南中医药大学药学院,长沙 410208,湖南;2中南大学湘雅三医院临床药理中心,中南大学湘雅三医院临床试验研究中心,长沙 410013,湖南;3药物临床评价技术国家地方联合工程实验室,长沙 410013,湖南;4中南大学医学伦理学研究中心,长沙 410013,湖南 
  • 收稿日期:2020-12-31 修回日期:2021-07-20 出版日期:2021-07-26 发布日期:2021-08-09
  • 通讯作者: 王晓敏,女,博士,助理研究员,研究方向:医学伦理学。 Tel: 0731-88618938 E-mail: xiaominwangcsu@163.com
  • 作者简介:欧阳晨溪,女,研究方向:临床药理学。 Tel: 0731-88618938 E-mail: oy1jessie@gmail.com
  • 基金资助:
    重大新药创制重大专项(2020ZX09201010)

Ethical issues and countermeasures of early phase trials

OUYANG Chenxi 1, HUANG Jie 2,3, XIANG Yuxia 2,3, WANG Xiaomin 2,3,4   

  1. 1 School of Pharmacy, Hunan Univeristy of Chinese Medicine, Changsha 410208, Hunan, China
  • Received:2020-12-31 Revised:2021-07-20 Online:2021-07-26 Published:2021-08-09

摘要: 早期临床试验是药物研发向临床转化的早期探索阶段,随着国家对创新药研发的大力鼓励以及企业的大力投入,大量创新药物进入早期临床试验,而早期临床试验一般基于创新的诊疗机制、制药技术和给药方法,且其研究设计方案复杂多样、计算机模拟等新技术在早期临床试验过程中也被广泛应用,这些方面是早期临床试验的科学性和伦理性审查面临的重大挑战。本文基于早期临床试验的特点,通过对早期临床试验中风险不确定性、治疗性误解、受试者补偿、突破性治疗等伦理问题进行分析,提出伦理对策和建议。

关键词: 早期临床试验, 伦理挑战, 对策探讨

Abstract: Early phase trials refer to the early exploratory stage of transferring drug development into clinical trials. With China's strong encouragement for innovative drug research and development and enterprises vigorous investment, a large number of innovative drugs have entered early clinical trials. Early phase trials are generally based on innovative diagnosis and treatment mechanisms, pharmaceutical technology and drug delivery methods. Their research design are complex and diverse, and the new technology such as computer simulation are also widely used in the early phase trial process. These aspects are major challenges for the scientific and ethical review of early phase trials. Based on the characteristics of early phase trials, this article analyzes the ethical issues in early clinical trials such as risk uncertainty, therapeutic misunderstanding, subject compensation, breakthrough treatment, etc., and puts forward ethical countermeasures and suggestions.

Key words: early clinical trials,  ethical challenges, countermeasures

中图分类号: